Target intelligence / Profile preview

Toll-like receptor 7, Toll-like receptor 9, and Vacuolar-type H+-ATPase (TLR7/9 and V-ATPase)

Target
TLR7/9 and V-ATPase
Molecular classification
Receptor, Enzyme, Proton pump
01

Overview

The endosomal/lysosomal acidification machinery, primarily driven by the vacuolar-type H+-ATPase (V-ATPase), is essential for the functional activation of Toll-like receptors 7 and 9 (TLR7/9) (Forgac, 2007). TLR7 and TLR9 are endosomal receptors that recognize single-stranded RNA and unmethylated CpG DNA, respectively, triggering innate immune responses and the production of type I interferons (Kuznik et al., 2011). Acidification of the endosomal lumen is a prerequisite for the proteolytic cleavage of TLR7/9 by resident proteases like cathepsins, a step necessary for their signaling competence (Schrezenmeier & Dörner, 2020). Drugs such as hydroxychloroquine and chloroquine act as lysosomotropic weak bases that accumulate within endosomes, increasing the internal pH and thereby inhibiting the acidification machinery. This disruption prevents the activation of TLR7/9, making this pathway a critical therapeutic target in autoimmune diseases like systemic lupus erythematosus (SLE) and rheumatoid arthritis (Wallace et al., 2012). Furthermore, this machinery is involved in viral entry and processing, providing a rationale for its investigation in infectious disease contexts.

Other names
TLR7TLR9V-ATPaseVacuolar-type H+-ATPaseEndosomal acidification machineryLysosomal acidification machinery
02

Mechanism of action

Inhibition of endosomal acidification (increasing pH), which prevents the proteolytic cleavage and activation of Toll-like receptor 7 and Toll-like receptor 9, thereby dampening the innate immune response (Schrezenmeier & Dörner, 2020).

03

Biological functions

Innate immune responseNucleic acid sensingSignal transductionProtein processingEndosomal pH regulation
04

Disease associations

Systemic lupus erythematosusRheumatoid arthritisViral infectionSjögren's syndromeMalaria
05

Safety considerations

Retinal toxicity (retinopathy)QT interval prolongationCardiomyopathyNeuromyopathyHypoglycemia
06

Interacting drugs

Hydroxychloroquine

4 more in the full profile.

07

Biomarkers

Type I interferon signatureAnti-double-stranded DNA (dsDNA) antibodiesEndosomal pH levelsSerum IFN-alpha

Beyond the preview

Go deeper on Toll-like receptor 7, Toll-like receptor 9, and Vacuolar-type H+-ATPase (TLR7/9 and V-ATPase).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Toll-like receptor 7, Toll-like receptor 9, and Vacuolar-type H+-ATPase (TLR7/9 and V-ATPase).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call